# New Studies Find Cannabis Reduces Alzheimer’s-Induced Agitation > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/new-studies-find-cannabis-reduces-alzheimers-induced-agitation/ > **Published:** 2026-07-25T12:17:07-04:00 | **Last Modified / Clinically Audited:** 2026-09-28T10:48:24-04:00 > **Clinical Summary:** New studies show cannabis may reduce Alzheimer's agitation. Learn what clinicians should know about THC/CBD for dementia behavioral symptoms. --- ✦ New CED Clinical Relevance #67 Notable Clinical Interest Emerging findings or policy developments worth monitoring closely. NeurologyAgingTHCCBDResearchMental HealthSafety Why This Matters Clinicians managing behavioral symptoms in Alzheimer’s disease patients now have preliminary evidence that cannabis may offer an effective alternative or adjunct to conventional antipsychotics, which carry significant adverse effects in this population. These findings could shift treatment conversations with patients and families seeking non-pharmacological or lower-risk pharmacological options for agitation that currently has limited evidence-based interventions. However, clinicians should note that larger, longer-duration studies and clarification of optimal THC/CBD ratios are needed before this becomes standard clinical practice. Clinical Summary Recent [clinical trials](https://cedclinic.com/endocannabinoid-system-emotional-memory-ptsd-treatment/) demonstrate that 12 weeks of [medical cannabis treatment](https://cedclinic.com/medical-cannabis-eligibility-book-appointment/) containing both THC and CBD reduced agitation in nearly 90% of Alzheimer’s disease patients who received active treatment, suggesting potential therapeutic benefit for this challenging behavioral symptom. Agitation and aggressive behavior in dementia patients significantly impair quality of life and caregiver burden while currently available pharmacological options are limited and often poorly tolerated. These findings are clinically relevant because behavioral disturbances in Alzheimer’s disease frequently necessitate antipsychotic medications, which carry substantial risks including increased mortality, stroke, and cognitive decline in elderly populations. The apparent efficacy of [cannabinoid therapy](https://cedclinic.com/unknown-cannabinoid-receptor-brain-damage-relief/) for agitation could offer clinicians an alternative or adjunctive approach for managing this common and distressing neuropsychiatric symptom in dementia patients. Clinicians considering cannabis for [Alzheimer’s-related agitation](https://cedclinic.com/cannabinoid-based-therapy-alzheimer-agitation-phase-2-trial/) should recognize these promising trial results while awaiting larger-scale studies to establish optimal dosing, long-term safety, and effects on other dementia-related symptoms or concurrent medications. Clinical Perspective 🧠 While preliminary findings suggesting cannabis may reduce agitation in Alzheimer’s disease warrant attention, clinicians should interpret these results cautiously given the small sample sizes typical of early-stage trials, lack of placebo-controlled comparisons in some studies, and heterogeneity in THC/CBD ratios used across research. The 90% response rate reported is notably high and should be viewed alongside potential confounders such as concurrent behavioral interventions, caregiver expectations, and the natural fluctuation of agitation symptoms in dementia populations. Additionally, cannabinoids carry real risks for older adults including [cognitive impairment](https://cedclinic.com/acute-effects-partial-cb1-receptor-agonists-cognition/), falls, drug interactions with common medications, and potential cardiovascular effects that may outweigh benefits in some patients. For now, cannabis might reasonably be considered as an adjunctive option for select patients with severe, treatment-resistant agitation after standard behavioral and pharmacological approaches have been exhausted and with careful monitoring, but robust 💬 Join the Conversation Have a question about how this applies to your situation? [Ask Dr. Caplan →](https://benjamincaplan.com/ask-dr-caplan) Want to discuss this topic with other patients and caregivers? [Join the forum discussion →](https://cedclinic.com/interact/discussion-forums/) Have thoughts on this? Share it: [X Share on X](https://twitter.com/intent/tweet?text=Just%20read%20this%20on%20CEDclinic.com%3A%20New%20Studies%20Find%20Cannabis%20Reduces%20Alzheimer%27s-Induced%20Agitation%20%40drcaplan&url=https%3A%2F%2Fcedclinic.com%2F%3Fp%3D71440)[in Share on LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A%2F%2Fcedclinic.com%2F%3Fp%3D71440)[🦅 Share on BlueSky](https://bsky.app/intent/compose?text=Just%20read%20this%3A%20New%20Studies%20Find%20Cannabis%20Reduces%20Alzheimer%27s-Induced%20Agitation%20via%20%40drcaplan.bsky.social%20https%3A%2F%2Fcedclinic.com%2F%3Fp%3D71440)[📷 Follow on Instagram](https://www.instagram.com/drbenjamincaplan)[📝 Read more on Substack](https://doctorapprovedcannabis.substack.com/)[🔔 Subscribe via RSS](https://cedclinic.com/feed/) Related Articles - [Schedules of Controlled Substances: Rescheduling FDA-Approved Cannabis Products](https://cedclinic.com/fda-approved-cannabis-products-rescheduling-schedule-iii/) - [420 with CNW – Study Finds That Marijuana Legalization Lowers Crime Rates](https://cedclinic.com/marijuana-legalization-lowers-crime-rates-study-insights/) - [Daily Digest: Cannabis Adolescent Psychiatric Risk Data Study](https://cedclinic.com/cannabis-adolescent-psychiatric-risk-data-study/) 📰 Source: [https://internationalcbc.com/new-studies-find-cannabis-reduces-alzheimers-induced-agitation/](https://internationalcbc.com/new-studies-find-cannabis-reduces-alzheimers-induced-agitation/) Further Reading CED Clinic Blog[Why Cannabis Works](https://cedclinic.com/why-cannabis-works/) Evidence Watch[Cannabis and Heart Health](https://cedclinic.com/cannabis-cardiovascular-health-study/) CED Clinic Blog[Cannabis for Sleep](https://cedclinic.com/cannabis-for-sleep/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Former CMO Canna Care Docs (250,000+ patients supervised), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).